Tesamorelin
The FDA-approved GHRH analog behind Egrifta
What tesamorelin is approved for, how it works, approved dosing, what the trials showed, side effects, and how it compares to research peptides like CJC-1295.
The mechanism
Like CJC-1295, it copies the brain's GHRH signal. Unlike CJC-1295, it went through full FDA approval.
Signals the pituitary
A stabilized GHRH that resists breakdown long enough for once-daily dosing.
GH pulses rise
Your own growth hormone rises in a natural, pulsing pattern, not the flat spike of GH injections.
Belly fat drops
Higher GH and IGF-1 selectively reduce visceral fat, the fat around the organs.
Approved vs off-label
The approval is real, but narrow.
HIV-associated belly fat
Reducing excess abdominal fat in adults with HIV and lipodystrophy. The label notes it is not for weight loss, and long-term heart safety hasn't been established.
Evidence: two Phase 3 trials
General fat loss, cognition, anti-aging
Not FDA-evaluated. A doctor can prescribe it off-label, but the evidence for these uses is much smaller.
Evidence: limited, mostly one cognition trial
What the trials showed
Belly fat measured by CT scan after 26 weeks, versus placebo.
Adults with HIV and excess abdominal fat. Triglycerides and cholesterol also improved.
Falutz et al., N Engl J Med 2007 (PMID 18057338); FDA label
A second trial confirming the effect, the basis for FDA approval.
EGRIFTA WR prescribing information (label)
In older adults, including some with mild cognitive impairment. One trial, not an approved use.
Baker et al., Arch Neurol 2012 (PMID 22869065)
Approved dosing
Every version is a once-daily injection under the skin of the belly.
The vial is mixed once a week and gives 7 daily doses. Smaller injection volume; replacing SV.
Mixed fresh each day. The two versions are not interchangeable.
The trials used the original 2mg formulation. "WR" means weekly reconstitution, not weekly injections.
Side effects and warnings
From the FDA label, 26-week placebo-controlled trials.
| Tesamorelin | Placebo | |
|---|---|---|
| Injection-site reactions | 17% | 6% |
| Joint pain | 13% | 11% |
| Muscle pain | 6% | 2% |
| Swelling (edema) | 6% | 2% |
| Tingling or numbness | 5% | 2% |
Not for use with active cancer, pituitary problems or in pregnancy. The label also warns about higher blood sugar, raised IGF-1 and fluid retention, so glucose and IGF-1 are monitored.

Prescription vs research versions
By prescription
Egrifta is a real, FDA-approved drug from a licensed prescriber and pharmacy, for the approved use or off-label at a doctor's discretion.
Research versions
"Tesamorelin" sold as a research chemical is not Egrifta and isn't FDA-evaluated for identity, purity or sterility.
Banned in sport
GHRH analogs, including tesamorelin, are on the WADA prohibited list.
Compared with the research-chemical option: tesamorelin vs CJC-1295 and the CJC-1295 profile.
What to monitor
- Waist measurement monthly; belly fat is the target
- IGF-1 and fasting glucose or HbA1c, as the label recommends
- Daily doses and any swelling, joint pain or tingling
The dashboard logs daily doses and symptoms, and Lab Analysis tracks IGF-1 and glucose over time.

Frequently asked questions
What is tesamorelin?
Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH) that signals the pituitary gland to release more of the body's own growth hormone. It is sold by prescription as Egrifta SV and Egrifta WR.
Is tesamorelin FDA-approved?
Yes, for one use: reducing excess abdominal (visceral) fat in adults with HIV-associated lipodystrophy. It was first approved in 2010. It is not approved for general weight loss, bodybuilding, anti-aging or cognitive enhancement, so those uses are off-label.
What is the approved tesamorelin dose?
Both current versions are once-daily injections under the skin of the abdomen: 1.28mg for Egrifta WR, whose vial is mixed once a week and provides seven doses, or 1.4mg for Egrifta SV, mixed daily. The two are not interchangeable. The original trials used a 2mg dose of an earlier formulation.
How well does tesamorelin work?
In the two 26-week Phase 3 trials behind its approval, visceral fat measured by CT fell 18% and 14% on tesamorelin, versus a 2% rise and a 2% drop on placebo. Triglycerides and cholesterol also improved in the first trial.
What are the side effects of tesamorelin?
In the label's 26-week trials, injection-site reactions occurred in 17% (versus 6% on placebo), joint pain in 13% (versus 11%), and muscle pain, swelling and tingling or numbness in 5 to 6% (versus 2%). It can also raise blood sugar and IGF-1, and it should not be used with active cancer, pituitary problems or during pregnancy.
What is the difference between Egrifta SV and Egrifta WR?
Both are FDA-approved tesamorelin injected once daily. Egrifta SV (1.4mg) is mixed fresh each day. Egrifta WR (1.28mg), approved in March 2025, is mixed once a week, uses less than half the injection volume, can be kept at room temperature and is replacing SV.
Is tesamorelin the same as CJC-1295?
No. Both are GHRH analogs acting on the same receptor, but they are different molecules. Tesamorelin is an FDA-approved prescription drug with Phase 3 trial data, while CJC-1295 has never been approved and is sold only as a research chemical.
Can tesamorelin be used for fat loss or cognition?
Only off-label, with a prescriber's judgment. A 20-week trial in older adults found improved executive function, and doctors sometimes prescribe it off-label for abdominal fat, but these uses have not been evaluated by the FDA, and the label states it is not indicated for weight loss.
Where to buy: Egrifta by prescription vs research vials, in where to buy tesamorelin.
Track your protocol
Log daily doses, waist measurements, IGF-1 and glucose in one place. Free.
Sources
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID 18057338
- EGRIFTA WR (tesamorelin) prescribing information: indication, dosing, warnings, adverse reactions and clinical studies. drugs.com
- Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012;69(11):1420-1429. PMID 22869065
- Theratechnologies receives FDA approval for EGRIFTA WR. March 2025. drugs.com
This content is for informational purposes only and is not medical advice. Tesamorelin (Egrifta) is FDA-approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy and is available only by prescription. Any other use is off-label. Research-chemical tesamorelin is not FDA-approved.